Amylyx Pharmaceuticals Tech Stack

Clinical-stage biotech advancing therapies for rare neurological and endocrine diseases

Pharmaceutical Manufacturing Cambridge, MA 51–200 employees Public Company

Amylyx is a public-company biotech at inflection point: moving from clinical development into commercial launch, with active Phase III and Phase I programs alongside a first endocrinology product entering the market. The hiring velocity is accelerating across research, healthcare, and leadership roles (9 director-level openings), and their tech stack reveals operational maturity typical of late-stage programs—NetSuite + Medidata Rave for trial management, LC-MS and HPLC for analytical chemistry, plus SAS/Python for biostatistics. Pain points cluster around launch readiness, regulatory timelines, and scaling compliant processes, all consistent with a company managing multiple clinical assets toward approval.

Tech Stack 12 technologies

Core StackNetSuite Smartsheet SAS Python FloQast Microsoft Office Adobe Acrobat SharePoint HPLC LC-MS Medidata Rave R

What Amylyx Pharmaceuticals Is Building

◆Challenges

High unmet medical needs
Improving patient access
Ensuring data integrity
Launch readiness for first product
Scalable compliant processes
Complex technical challenges
Inefficient marketing operations
Regulatory timeline management
Scaling contracting operations
Preparing for drug launch

▲Active Projects

Advisory board meetings
Patient access presentations
Medical affairs strategy
Field medical enablement
Payer presentations
Commercial launch of first endocrinology product
Phase iii synthetic peptide avexitide
Phase i antisense oligonucleotide amx0114
Enterprise-wide omnichannel vision
Clinical site identification

Hiring Activity

Accelerating20 roles · 10 in 30d

Department

Healthcare

Research

Legal

Ops

Product

Data

Finance

Seniority

Director

Senior

Junior

Manager

Notable leadership hires: Scientific Director, Director CMC

Company intelligence

Find more companies like Amylyx Pharmaceuticals by tech stack, pain points and active projects

Get started free

About Amylyx Pharmaceuticals

Amylyx develops novel therapies targeting rare diseases with limited treatment options, with current focus on amyotrophic lateral sclerosis (ALS), Wolfram syndrome, and post-bariatric hypoglycemia. The company operates as a public clinical-stage biotech headquartered in Cambridge, MA, with hiring footprint spanning the United States, Canada, and Peru. Active programs include a Phase III synthetic peptide program (avexitide), Phase I antisense oligonucleotide (amx0114), and preparations for commercial launch of their first endocrinology asset. Their operational infrastructure spans clinical trial management, regulatory strategy, medical affairs, and early-stage go-to-market planning across payer and patient access channels.

HeadquartersCambridge, MA

Company Size51–200 employees

Hiring MarketsUnited States, Canada, Peru

Frequently Asked Questions

What is Amylyx Pharmaceuticals working on?

Amylyx is advancing two clinical programs: Phase III avexitide (synthetic peptide) and Phase I amx0114 (antisense oligonucleotide), plus preparing commercial launch of their first endocrinology product. Focus areas span ALS, Wolfram syndrome, and post-bariatric hypoglycemia.

What tech does Amylyx use for drug development?

Amylyx uses Medidata Rave for clinical trial management, HPLC and LC-MS for analytical chemistry, SAS and Python for biostatistics, and NetSuite for enterprise operations. FloQast handles financial close.